Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

JF De Groot, MR Gilbert, K Aldape, KR Hess… - Journal of neuro …, 2008 - Springer
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …
被引用次数：125 相关文章

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

JF Groot, MR Gilbert, K Aldape… - Journal of neuro …, 2008 - mdanderson.elsevierpure.com
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

JF de Groot, MR Gilbert, K Aldape… - Journal of neuro …, 2008 - pubmed.ncbi.nlm.nih.gov
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.

JF de Groot, MR Gilbert, K Aldape, KR Hess… - Journal of Neuro …, 2008 - europepmc.org
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

[引用][C] Phase II study of carboplatin and erlotinib (Tarceva. OSI-774) in patients with recurrent glioblastoma

JF DE GROOT - J Neurooncol, 2008 - cir.nii.ac.jp
[PDF] academia.edu

[PDF][PDF] Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

JF de Groot, MR Gilbert, K Aldape, KR Hess… - J Neurooncol, 2008 - academia.edu
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

JF de Groot, MR Gilbert, K Aldape… - Journal of Neuro …, 2008 - search.proquest.com
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …
[HTML] nih.gov

[HTML][HTML] Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

JF de Groot, MR Gilbert, K Aldape, KR Hess… - Journal of neuro …, 2008 - ncbi.nlm.nih.gov
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

JF Groot, MR Gilbert, K Aldape… - Journal of Neuro …, 2008 - ohiostate.elsevierpure.com
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

JF Groot, MR Gilbert, K Aldape, KR Hess… - Journal of Neuro …, 2008 - infona.pl
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …